Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

Sponsor
Second Xiangya Hospital of Central South University
Study ID
NCT03011008
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
  • Insulin — DRUG
    Receive insulin following clinician's instruction.

Study Details

The purpose of this study is to investigate the therapeutic effect of Liraglutide on autoimmune diabetes.

Key Dates

Start date
Jan 31, 2017
Status verified
Mar 2020
Primary completion
Dec 31, 2020
Completion
Jun 30, 2021

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide + insulin
    Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
  • Active Comparator: Insulin
    Patients will receive insulin injection as a routine therapy.

Primary Outcome Measure

Mean amplitude of glycemic excursions (MAGE) [ Time Frame: 1 year ]

Central Contacts

Related Studies